La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Sleep Number a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Sleep Number..

Sleep Number (NASDAQ:SNBR) Azioni, Catena delle Opzioni

Sleep Number

Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.

Sleep Number Corp

SLEEP NUMBER ORD

WIIM

SMCI

Super Micro Computer shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and cut its price target on the stock from $50 to $23.

Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) reported quarterly earnings of $3.37 per share which missed the analyst consensus estimate of $3.48 by 3.16 percent. This is a 3.71 percent decrease over earnings of $3.50 per share from the same period last year. The company reported quarterly sales of $1.77 billion which missed the analyst consensus estimate of $1.87 billion by 5.65 percent. This is a 7.94 percent increase over sales of $1.64 billion the same period last year.

Earnings

Earnings Misses

News

Pinnacle West Capital Q3 2024 GAAP EPS $3.37 Misses $3.48 Estimate, Sales $1.77B Miss $1.87B Estimate

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)
IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet's FHAB platform which Sonnet believes could&nbsp;present an important oncology possibility
The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic biologics target to IL-18 generating multiple novel cancer drugs
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,134,635 entitled "Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same," covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant). The patent carries a term effective until June 2044.

Biotech

General

SONN

Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates; Both Novel Bifunctional And Monofunctional Fusion Proteins Exhibit Wild-Type Binding To The IL-18 Receptor, Coupled With Undetectable Binding To The Inhibitory IL-18 Binding Protein

ANIX

Anixa Biosciences Sets November 8 For Public Release Of Phase 1 Breast Cancer Vaccine Data At SITC Annual Meeting

TD Cowen analyst Nick Yako maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Hold and raises the price target from $130 to $150.

Price Target

Analyst Ratings

QLYS

TD Cowen Maintains Hold on Qualys, Raises Price Target to $150

Management

FTHM

Fathom Holdings Announced It Has Promoted Joanne Zach To CFO

<ul>
<li>$800 Million AAA-Rated Personal Loan and $200 Million AA-Rated Auto Loan Asset Backed Securitizations, with $5.5 Billion raised across all ABS transactions year-to-date</li>
<li>Pagaya remains the #1 personal loan ABS issuer in the U.S.</li>
</ul>
Pagaya Technologies LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) ("Pagaya" or "the Company"), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the closing of PAID 2024-10 and RPM 2024-3, totaling $1 billion in size across both deals. This represents the Company's fourth AAA-rated personal loan ABS transaction and its first AA-rated auto ABS transaction.
A total of 28 unique investors participated across these two transactions, the majority of which were repeat investors. The deal was substantially oversubscribed, reflecting continued strong investor demand for Pagaya's robust, AI-enabled consumer credit assets.
Pagaya continues to meet the needs of prominent financial institutions and deliver efficient, fit-for-market structures across the financial ecosystem. Qualified institutional buyers purchased notes backed by personal and auto loans that will be originated by Pagaya's lending partners on Pagaya's AI-powered network.

Pagaya Raises $1B Across Two New Personal Loan And Auto ABS Deals, Signaling Strong Capital Markets Demand; A Total Of 28 Investors Participated Across These Two Transactions, The Majority Of Which Were Repeat Investors

Cummins shares are trading higher after Baird raised its price target on the stock from $330 to $372.

MFA Finl Q3 2024 Distributable EPS $0.37, NII $50.625M

GlobalFoundries shares are trading higher. Baird maintained an Outperform rating on the stock.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580f253b846faa000139ba71/robert-moskow">TD Cowen analyst Robert Moskow</a> upgraded the rating for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170. Clorox shares closed at $162.42 on Tuesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Trevor Young upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Underweight to Equal-Weight and raised the price target from $17 to $25. Revolve shares closed at $26.02 on Tuesday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/616e99feb650db000151570b/rick-bienkowski">Leerink Partners analyst Rick Bienkowski</a> upgraded the rating for Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and increased the price target from $27 to $39. Beam Therapeutics shares closed at $23.93 on Tuesday. <a href="https://www.benzinga.com/quote/BEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst David Begleiter upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowered the price target from $135 to $110. Celanese shares closed at $91.00 on Tuesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>

Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png" alt="" class="wp-image-632747" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49.png 1230w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

BEAM

RVLV

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

TSLA

Tesla shares are trading higher following Donald Trump's successful presidential election campaign.

Guidance

CVS Executive Says Company Is Not Providing A Formal Outlook For 2024 At This Stage

Chubb shares are trading higher. Wells Fargo raised its price target on the stock from $106 to $108.

Health Care

STXS

Stereotaxis Announces University Of Kansas Medical Center Physicians Have Treated The First Patients Using The Company's Genesis Robotic Magnetic Navigation System

Aflac shares are trading higher. Wells Fargo raised its price target on the stock from $106 to $107.

TD Cowen analyst Oliver Chen downgrades Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) from Buy to Hold and lowers the price target from $25 to $16.

Downgrades

TD Cowen Downgrades Grocery Outlet Holding to Hold, Lowers Price Target to $16

Contracts

YYGH

YY Group Holding's Hong Ye Group Announces SGD$4.7M In Contracts

TD Cowen analyst Vivien Azer downgrades Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) from Buy to Hold and lowers the price target from $50 to $48.

BF/B

TD Cowen Downgrades Brown-Forman to Hold, Lowers Price Target to $48

CHTR

Charter Communications shares are trading higher after Benchmark maintained a Buy rating on the stock and raised its price target from $440 to $450.

Sleep Number GAAP EPS of -$0.14 beats by $0.07, revenue of $426.62M misses by $19.34M

17:37 EDT Sleep Number (SNBR) sees Q4 gross margin 59%-60% vs. 60.8% in Q3 Published first on TheFly – the ultimate source for real-time, market-mo...

Sleep Number sees Q4 gross margin 59%-60% vs. 60.8% in Q3

Says continuing to advance initiatives in gross margins and EBITDA to deliver on targets. Published first on TheFly – the ultimate source for real-...

Sleep Number CEO says expected sequential improvement did not materialize

Says advertising needs to have greater efficiency with less consumer in que to buy a mattress. Says seeing delayed decision making by consumers – s...

Sleep Number CEO says need to be more efficient with media spend

17:33 EDT Sleep Number (SNBR) down 5% at $12.58 after Q3 results, reduced EBITDA view Published first on TheFly – the ultimate source for real-time...

Sleep Number down 5% at $12.58 after Q3 results, reduced EBITDA view

Sleep Number Corporation (SNBR) Q3 2024 Earnings Call Transcript

Sleep Number Corp ( ($SNBR) ) has realeased its Q3 earnings. Here is a breakdown of the information Sleep Number Corp presented to its investors. S...

Sleep Number Reports Q3 2024 Results Amid CEO Transition

In a report released today, Peter Keith from Piper Sandler maintained a Hold rating on Sleep Number (SNBR – Research Report), with a price target o...

Piper Sandler Keeps Their Hold Rating on Sleep Number (SNBR)

Piper Sandler lowered the firm's price target on Sleep Number (SNBR) to $12 from $16 and keeps a Neutral rating on the shares following Q3 that saw...

Sleep Number price target lowered to $12 from $16 at Piper Sandler

Sleep Number rallies after activist investor Stadium Capital boosts its stake

SNBR

Press Releases

Sleep Number Introduces New c1 Smart Bed, Providing Smart Adjustability at an Exceptional Value

Sleep Number Corporation to Announce Second Quarter 2024 Results on July 31st

Sleep Number Announces Second Quarter 2024 Results

MedtechWOMEN Announces Deborah Kilpatrick as Winner of the 2024 Ferolyn Powell Award

Sleep Number Introduces ClimateCool™ Smart Bed: Actively Cools and Effortlessly Adjusts for Deeper, More Comfortable Sleep

Sleep Number Honors World Menopause Day with Hot Flash Sale, New Innovations from Temperature Research to Enhance Women's Wellbeing and Their Partners

Comments

Sleep Number

Sleep Number (SNBR) Opzioni

Sleep Number (NASDAQ:SNBR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO